Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors
- Conditions
- Advanced Solid TumorMetastatic Solid TumorAdvanced and/or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- InSilico Medicine Hong Kong Limited
- Target Recruit Count
- 159
- Registration Number
- NCT06724042
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors
- Conditions
- Metastatic Malignant Solid TumorMalignant MesotheliomaAdvanced Solid Tumor
- Interventions
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- InSilico Medicine Hong Kong Limited
- Target Recruit Count
- 82
- Registration Number
- NCT06566079
- Locations
- 🇺🇸
Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
🇺🇸SCRI Oncology Partners, Nashville, Tennessee, United States
Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma
- Conditions
- Advanced Solid TumorsRelapsed/Refractory B-cell Lymphoma
- Interventions
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- InSilico Medicine Hong Kong Limited
- Target Recruit Count
- 60
- Registration Number
- NCT06445517
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Shanghai Jiao Tong University School of Medicine-Ruijin Hospital, Shanghai, Shanghai, China
Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- InSilico Medicine Hong Kong Limited
- Target Recruit Count
- 80
- Registration Number
- NCT06414460
- Locations
- 🇺🇸
Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Jiangsu Provincial People's Hospital, Nanjing, Jiangsu, China
Study Evaluating ISM5411 Administered Orally to Healthy Volunteers
- First Posted Date
- 2023-08-25
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- InSilico Medicine Hong Kong Limited
- Target Recruit Count
- 79
- Registration Number
- NCT06012578
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- InSilico Medicine Hong Kong Limited
- Target Recruit Count
- 60
- Registration Number
- NCT05975983
- Locations
- 🇺🇸
Bogan Sleep Consultants, LLC, Columbia, South Carolina, United States
🇺🇸Keck School of Medicine of USC, Los Angeles, California, United States
🇺🇸University of Oklahoma Health Sciences Center (OUHSC), Oklahoma City, Oklahoma, United States
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-07-11
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- InSilico Medicine Hong Kong Limited
- Target Recruit Count
- 70
- Registration Number
- NCT05938920
- Locations
- 🇨🇳
Anhui Chest Hospital, Hefei, Anhui, China
🇨🇳The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Peking University Shougang Hospital, Beijing, Beijing, China
A Phase 1, Evaluate the Safety, Tolerability, and Pharmacokinetics of INS018_055 in Healthy Subjects
- First Posted Date
- 2021-12-13
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- InSilico Medicine Hong Kong Limited
- Target Recruit Count
- 78
- Registration Number
- NCT05154240
- Locations
- 🇳🇿
NZCR Ltd, Christchurch, New Zealand